Lorem ipsum dolor sit amet consectetuer
We aim to develop a broad portfolio of antibody drugs that address unmet medical needs. Our programs follow stric R&D principles to maximize the likelihood of success – from selecting targets backed by strong genetic evidences, discovering lead molecules through rigorous scientific investigation, to improving developability of drug candidates by antibody enginerring.
Our Current Pipeline
Project phase
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
Our Approach
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
Results
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
Results
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
Results
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
| Program | Target | Indication | Drug discovery | Ind-enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| MWTX 01 | undiscolosed target | hematology | |||||
| MWTX 02 | undiscolosed target | hematology/complement system | |||||
| MWTX 03 | undiscolosed target | ||||||